Jazeta

Sitagliptin Hydrochloride, the active ingredient in Jazeta, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to improve blood glucose levels when combined with diet and exercise, and lifestyle modifications, under medical supervision. The drug works by enhancing incretin activity.

GNH USA supplies Jazeta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on quality assurance, regulatory compliance, and reliable global logistics for consistent product availability.

Jazeta (sitagliptin) is used in the treatment of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance.

- Type 2 diabetes mellitus: improves glycemic control when added to diet and exercise. - Monotherapy in metformin‑intolerant patients: provides an oral option for glucose lowering without metformin. - Combination therapy with other antidiabetics: can be co‑administered with sulfonylureas, insulin or thiazolidinediones to achieve target HbA1c.

Sitagliptin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea - Headache - Nasopharyngitis

Serious or Rare Side Effects: - Pancreatitis - Severe allergic reactions (e.g., angioedema, anaphylaxis) - Bullous pemphigoid

When prescribing sitagliptin, clinicians should consider several safety precautions to minimize risk.

- Renal function: assess baseline renal function and adjust dosing in moderate to severe impairment. - Pancreatitis: monitor for signs such as persistent abdominal pain and discontinue if suspected. - Hypersensitivity: discontinue at first indication of rash, angioedema, or anaphylaxis. - Elderly patients: use with caution due to potential for reduced renal clearance. - Concomitant insulin or sulfonylureas: monitor for hypoglycemia and adjust co‑medication as needed. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Sitagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase sitagliptin exposure. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): markedly raise plasma concentrations. - Insulin or sulfonylureas: heightened risk of hypoglycemia. - High‑dose DPP‑4 inhibitors: additive effect not recommended.

Moderate Interactions (Monitor Closely): - ACE inhibitors and ARBs: may enhance antihypertensive effect. - Diuretics: monitor electrolytes and renal function. - Warfarin: occasional changes in INR, require monitoring.